BSE Live
Feb 05, 16:01Prev. Close
1211.70
Open Price
1225.25
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Feb 05, 15:49Prev. Close
1212.70
Open Price
1212.70
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
1181.60 (5729)
| Cash Flow of Aurobindo Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 752.25 | 72.62 | 291.74 | 206.42 | 98.56 | |
| Net CashFlow From Operating Activities | 428.74 | 136.03 | 158.72 | 18.65 | -9.05 | |
| Net Cash Used In Investing Activities | -399.02 | -406.28 | -75.01 | -513.32 | -231.19 | |
| Net Cash Used From Financing Activities | -87.60 | 164.99 | -217.55 | 683.88 | 372.82 | |
| Foreign Exchange Gains / Losses | 1.66 | -33.46 | -0.97 | 0.76 | 4.34 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | -56.22 | -138.72 | -134.81 | 189.97 | 136.92 | |
| Cash And Cash Equivalents Begin of Year | 103.41 | 235.68 | 374.75 | 196.18 | 59.38 | |
| Cash And Cash Equivalents End Of Year | 47.19 | 96.96 | 239.94 | 386.15 | 196.30 |
02.02.2026
01.02.2026
Chartist Talk: Sudeep Shah bets on Indus Towers, Nestle India, City Union Bank for Budget day
07.01.2026
02.01.2026
12.11.2025
Aurobindo Pharm Standalone September 2025 Net Sales at Rs 2,789.72 crore, down 1.23% Y-o-Y
07.11.2025
Aurobindo Pharm Consolidated September 2025 Net Sales at Rs 8,285.70 crore, up 6.28% Y-o-Y
12.08.2025
Aurobindo Pharm Consolidated June 2025 Net Sales at Rs 7,868.14 crore, up 3.98% Y-o-Y
05.08.2025
Aurobindo Pharm Standalone June 2025 Net Sales at Rs 2,848.17 crore, up 15.78% Y-o-Y
14.07.2023
Cipla Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
14.07.2023
Aurobindo Pharma Q1 PAT seen up 6.1% YoY to Rs. 552.3 cr: Prabhudas Lilladher
13.07.2022
Aurobindo Q1 PAT may dip 26.1% YoY to Rs 568.8 cr: ICICI Direct
08.07.2022
Aurobindo Pharma Q1 PAT may dip 20.7% YoY to Rs 610.7 cr: Prabhudas Lilladher
11.02.2019
Analysts remain positive on Aurobindo Pharma, expect stock to return 8-30% after Q3 earnings
25.08.2018
Pharma Q1 review: Brokerages say performance a mixed bag, but are upbeat on domestic biz
10.08.2017
When Rakesh Jhunjhunwala grilled Aurobindo Pharma top brass after muted Q1 results
24.08.2016
Aurobindo to see growth in H2; capacity constraints continue: PL